自体造血干细胞移植联合大剂量化疗治疗卵巢癌  

Auto-hematopoietic stem cell transplantation with high-dose chemotherapy in treatment of ovarian cancer

作　　者：曹红花[1] 何明生[1] 

机构地区：[1]云南省肿瘤医院血液科,云南昆明650118

出　　处：《国际内科学杂志》2007年第8期486-488,共3页International Journal of Internal Medicine

摘　　要：卵巢癌的治疗是妇科恶性肿瘤中较棘手的问题。70%～80%初诊卵巢癌患者已Ⅲ期和Ⅳ期,常规联合化疗有效率较高,但5年生存率很低。自体造血干细胞移植联合大剂量化疗治疗卵巢癌的结果表明,晚期卵巢癌患者以及难治性和复发的卵巢癌患者接受移植后的疗效较好且毒副作用小。Treatment of ovarian cancer is a formidable problem in gynecologic malignant tumors. Seventy to eighty percent first diagnosed ovarian cancer is in stage Ⅲ～Ⅳ. Effective rate of conventional combined chemotherapy is high, but five-year survival rate is low. The treatment of auto-hematopoietic stem cell transplantation （AHSCT） with high-dose chemotherapy （HDC） is effective and has little side effect for the parents of advanced, refractory or recurrent ovarian cancers.

关 键 词：造血干细胞移植 卵巢癌 化学疗法 

分 类 号：R737.31[医药卫生—肿瘤]